Biochemical recurrences (BCR) of PCa occur in 27–53% of patients treated with RP or RT [2], depending on various risk factors, such as a high Gleason score (GS), a short PSA doubling time (PSAdt), and status of surgical margins or locally advanced disease [3–5]. The gene discussed is KLK3; the disease is posterior cortical atrophy.